Investment Analysts’ Weekly Ratings Updates for Capricor Therapeutics (CAPR)
by Michael Walen · The Markets DailySeveral brokerages have updated their recommendations and price targets on shares of Capricor Therapeutics (NASDAQ: CAPR) in the last few weeks:
- 12/22/2025 – Capricor Therapeutics had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
- 12/15/2025 – Capricor Therapeutics had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
- 12/15/2025 – Capricor Therapeutics was given a new $50.00 price target on by analysts at UBS Group AG.
- 12/15/2025 – Capricor Therapeutics had its “buy” rating reaffirmed by analysts at B. Riley. They now have a $50.00 price target on the stock, up previously from $21.00.
- 12/10/2025 – Capricor Therapeutics had its “overweight” rating reaffirmed by analysts at Piper Sandler. They now have a $45.00 price target on the stock, up previously from $20.00.
- 12/8/2025 – Capricor Therapeutics had its price target raised by analysts at Oppenheimer Holdings, Inc. from $22.00 to $54.00. They now have an “outperform” rating on the stock.
- 12/4/2025 – Capricor Therapeutics had its price target raised by analysts at Maxim Group from $25.00 to $50.00. They now have a “buy” rating on the stock.
- 12/3/2025 – Capricor Therapeutics was given a new $48.00 price target on by analysts at Industrial Alliance Securities.
- 12/3/2025 – Capricor Therapeutics had its “buy” rating reaffirmed by analysts at Alliance Global Partners.
- 12/3/2025 – Capricor Therapeutics had its price target raised by analysts at HC Wainwright from $24.00 to $60.00. They now have a “buy” rating on the stock.
- 11/11/2025 – Capricor Therapeutics had its price target raised by analysts at Roth Capital from $12.00 to $13.00. They now have a “buy” rating on the stock.
Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.
The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.